Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vibegron vs placebo in Chinese patients with overactive bladder
CTR20230702Phase 3Terminated
- Sponsor
- Sinovant Sciences
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of vibegron in overactive bladder (OAB), sponsored by Sinovant Sciences. Started Mar 2023; status: terminated.
02
Drugs
vibegron
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on CTR20230702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230702.